Study of the Impact of an Intervention Performed by a Clinical Pharmacist on Patients at Risk of Pneumococcal Infection at the End of Hospitalization

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04734925

Acronym

IP-VAC

Enrollment

167

Registered

2021-02-02

Start date

2020-03-01

Completion date

2020-10-22

Last updated

2025-12-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vaccination

Keywords

antipneumococcal

Brief summary

In France, Streptococcus pneumoniae is the leading agent involved in community-acquired bacterial pneumopathies and bacterial meningitis. The frequency of these infections is increasing in at-risk subjects. Paradoxically, pneumococcal vaccination coverage in this type of patient is limited at the national level, even though the French High Council for Public Health (HCSP) has been extending the 13-valent conjugate and 23-valent non-conjugate double vaccination in this target population since March 2017. These patients generally benefit from regular medical follow-up involving several health professionals in hospital or outpatient clinics. In spite of this, one of the factors identified as a hindrance to pneumococcal vaccination is the absence of a proposal from the doctor. We would like to assess compliance with the recommendations for pneumococcal vaccination according to the High Council of Public Health (HCSP) in at-risk patients leaving hospital. We also wish to measure the potential impact of an intervention by the clinical pharmacist on the application of these recommendations.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Inclusion criteria

* Hospitalization in one of the departments participating in the study * At risk of pneumococcal infection according to HCSP recommendations (1) * Negative pneumococcal vaccination status * Adult patient (≥18 years old)

Exclusion criteria

* Under safeguard of justice * Unable to receive informed information * Patient having objected to the use of their data.

Design outcomes

Primary

Measure	Time frame	Description
vaccine protocols dispensed by dispensing pharmacists.	3 month	number of vaccine protocols

Countries

France

Outcome results